Shareholders approved all proposals of the Board of Directors Severin Schwan was re-elected as Chairman of the Board of Directors; all other Board members standing for election were confirmed 38th consecutive dividend increase to CHF 9.70 per share Basel, 25 March 2025 – Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that its shareholders had... Read more
New Evrysdi five-year data from the SUNFISH study showed continued stabilisation of motor function in a broad population of individuals with Types 2 or 3 spinal muscular atrophy (SMA) Late-breaking oral on Elevidys’ Embark two-year data and pooled analysis of Study 101, 102 and Endeavor, demonstrated clinically meaningful and statistically significant improvements across key measures... Read more
Agreement allows for a range of potentially best-in-class therapy options as monotherapy and fixed dose combination with Roche`s lead incretin asset CT 388 Collaboration will complement Roche’s portfolio in the field of cardiovascular, renal, and metabolic (CVRM) diseases Obesity is a heterogeneous disease with over 200 related comorbidities, including cardiovascular and metabolic diseases, and is... Read more
The new center will be a hub for both Roche and Genentech, bringing together expertise in Cardiovascular, Renal, and Metabolism, as well as for data science and AI specialists to drive innovation in drug discovery and development Roche will be the first to join Harvard’s Enterprise Research Campus in Allston, taking a suite in the... Read more
Gazyva/Gazyvaro is the only anti-CD20 monoclonal antibody in a randomised phase III study to demonstrate a complete renal response benefit1 The filing application is based on data from the phase III REGENCY study, where Gazyva/Gazyvaro showed superiority over standard therapy alone in people with active lupus nephritis1 Lupus nephritis affects 1.7 million people worldwide; up... Read more
First-ever head-to-head trial comparing Xolair and oral immunotherapy (OIT) Results were featured as late-breakers at the 2025 AAAAI Annual Meeting Xolair is the only US FDA-approved medicine to reduce allergic reactions in children and adults with one or more food allergies Basel, 2 March 2025 – Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today new... Read more
Columvi plus chemotherapy showed a 41% reduction in the risk of death in the pivotal phase III STARGLO study1,2 DLBCL—an aggressive disease with a high risk of progression—remains an area of high unmet need, especially for treatments that can be initiated soon after the cancer returns If approved, this off-the-shelf, fixed-duration Columvi combination will be... Read more
Roche’s innovative sequencing by expansion (SBX) technology represents a leap forward in next-generation sequencing (NGS), which is playing a vital role in decoding complex diseases like cancer, immune disorders and neurodegenerative conditions Combined with an innovative, high throughput sensor module, SBX uses expanded synthetic molecules to determine the DNA sequence of a target molecule, creating... Read more
Evrysdi is the only non-invasive disease-modifying SMA treatment and is approved in over 100 countries Evrysdi tablet can be stored at room temperature and offers the same demonstrated efficacy and safety as the currently available oral solution New tablet formulation may provide greater freedom and independence for people with SMA thanks to simplified dose administration... Read more
Nearly half of patients on Gazyva/Gazyvaro plus standard therapy achieved a complete renal response (CRR), with a statistically significant and clinically meaningful improvement, compared to standard treatment alone1 Analysis showed consistent CRR benefit across patient subgroups, highlighting potential to treat a broad patient population with high unmet need1 Gazyva/Gazyvaro is the only anti-CD20 monoclonal antibody... Read more